CAH - Dividend announcements

Revenue increased 11% to $60.9 billionGAAP1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69Non-GAAP operating earnings increased 18% to $956 million; non-GAAP diluted EPS increased 35% to $3.17Cardinal Health raises and narrows fiscal year 2026 non-GAAP EPS guidance2 to $10.70 to $10.80Cardinal Health reduces debt and completes additional $250 million share repurchase, bringing FY26 repurchase total to $1.0 billionDUBLIN, Ohio, April 30, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of fiscal year 2025.Third quarter GAAP operating earn

DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of

Revenue increased 22% to $64 billionGAAP1 operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88Non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments; non-GAAP diluted EPS increased 36% to $2.55Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $9.65 to $9.85 and fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billionCardinal Health anticipates completing the acquisition of Solaris Health in early NovemberDUBLIN, Ohio, Oct. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2026 revenues

DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op

Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expirationGAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00GI Alliance announces expansion into urology specialty therapeutic areaDUBLIN, Ohio, May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion,

DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nucle

Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $549 million; GAAP diluted EPS was $1.65Non-GAAP operating earnings increased 9% to $635 million, driven by the Pharmaceutical and Specialty Solutions segment; non-GAAP diluted EPS increased 2% to $1.93Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.85 to $8.00, from $7.75 to $7.90Company announces the completion of its acquisition of 73% ownership of GI AllianceDUBLIN, Ohio, Jan. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported second quarter fiscal year 2025 revenues of $55.3 billion, a decrea

DUBLIN, Ohio, Nov. 5, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2025 to shareholders of record at the close of business on January 2, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $568 million; GAAP diluted EPS was $1.70Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profitNon-GAAP diluted EPS increased 9% to $1.88Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.75 to $7.90, from $7.55 to $7.70DUBLIN, Ohio, Nov. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2025 revenue of $52.3 billion, a decrease of 4% from the first quarter of fiscal year 2024. First qu

DUBLIN, Ohio, Aug. 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on October 15, 2024 to shareholders of record at the close of business on October 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business

Fourth quarter revenue increased 12% to $59.9 billionFourth quarter GAAP1 operating earnings were $401 million and GAAP diluted EPS was $0.96Fourth quarter non-GAAP operating earnings increased 14% to $605 million and non-GAAP diluted EPS increased 29% to $1.84Fiscal Year 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectivelyFiscal year 2025 non-GAAP EPS guidance raised to $7.55 to $7.70, from at least $7.50DUBLIN, Ohio, Aug. 14, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2024 revenues of $59.9 billion, an increase of 12% from the prior year. GAAP operating earnings were $401 m

DUBLIN, Ohio, May 7, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the close of business on July 1, 2024. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With more than 50 year

Revenue increased 9% to $54.9 billionGAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08Fiscal year 2024 non-GAAP EPS guidance2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50DUBLIN, Ohio, May 2, 2024  /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were

DUBLIN, Ohio, Feb. 6, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2024 to shareholders of record at the close of business on April 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, ope

Revenue increased 12% to $57.4 billionGAAP1 operating earnings were $482 million; GAAP diluted EPS was $1.43Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS increased 38% to $1.82Fiscal 2024 non-GAAP EPS guidance raised to $7.20 to $7.35, from $6.75 to $7.002,3Fiscal 2024 non-GAAP adjusted free cash flow guidance raised to ~$2.5 billion, from ~$2.0 billionCardinal Health to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organizationDUBLIN, Ohio, Feb. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported second quarter fiscal 2024 revenue of $57.4 billion, an increase of 12% from the second

DUBLIN, Ohio, Nov. 14, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2024 to shareholders of record at the close of business on January 2, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in busines

Fourth quarter revenue increased 13% to $53.5 billionFourth quarter GAAP1 operating earnings were $137 million and GAAP diluted loss per share was $0.25 Fourth quarter non-GAAP operating earnings increased 24% to $560 million and non-GAAP diluted EPS increased 48% to $1.55Fourth quarter Pharmaceutical segment profit increased 12% to $504 million and Medical segment profit increased to $82 million Generated both operating cash flow and non-GAAP adjusted free cash flow of $2.8 billion and returned over $2.5 billion to shareholders in fiscal year 20232Fiscal year 2024 non-GAAP EPS guidance raised to $6.50 to $6.75, from $6.45 to $6.70DUBLIN, Ohio, Aug. 15, 2023 /PRNewswire/ -- Cardinal Health (

DUBLIN, Ohio, Aug. 9, 2023 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on October 15, 2023 to shareholders of record at the close of business on October 3, 2023. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business,

DUBLIN, Ohio, May 11, 2023 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to the Company's quarterly dividend, to $0.5006 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2023 to shareholders of record at the close of business on July 3, 2023. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 yea

Revenue increased 13% to $50.5 billionGAAP1 operating earnings were $572 million; GAAP diluted EPS was $1.34Non-GAAP operating earnings increased 11% to $606 million; non-GAAP diluted EPS increased 20% to $1.74Fiscal year 2023 non-GAAP EPS guidance raised and narrowed to $5.60 to $5.80, from $5.20 to $5.50Fiscal year 2023 adjusted free cash flow guidance raised and narrowed to $2.0 to $2.3 billion, from $1.5 to $2.0 billionDUBLIN, Ohio, May 4, 2023 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2023 revenues of $50.5 billion, an increase of 13% from the third quarter of fiscal year 2022. Third quarter GAAP operating earnings were $572 million and GAAP dil

DUBLIN, Ohio, Feb. 10, 2023 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.4957 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2023 to shareholders of record at the close of business on April 3, 2023. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations

Revenue increased 13% to $51.5 billionGAAP1 operating loss was $119 million due to a non-cash, pre-tax goodwill impairment of $709 million related to the Medical segment; GAAP diluted loss per share was $0.50Non-GAAP operating earnings of $467 million were in-line with the second quarter of last year; non-GAAP diluted EPS increased 4% to $1.32Fiscal year 2023 non-GAAP EPS guidance raised to $5.20 to $5.50, from $5.05 to $5.40DUBLIN, Ohio, Feb. 2, 2023 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported second quarter fiscal year 2023 revenues of $51.5 billion, an increase of 13% from the second quarter of fiscal year 2022. Second quarter GAAP operating loss was $119 million due to a no

DUBLIN, Ohio, Nov. 8, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.4957 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2023 to shareholders of record at the close of business on January 3, 2023. About Cardinal Health Cardinal Health (NYSE:CAH) is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in busine

DUBLIN, Ohio, May 10, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.4957 per share out of the Company's capital surplus. The dividend will be payable on July 15, 2022 to shareholders of record at the close of business on July 1, 2022. About Cardinal Health Cardinal Health (NYSE:CAH) is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, op

Revenue increased 14% to $44.8 billionGAAP1 operating loss was $97 million due to a non-cash, pre-tax goodwill impairment of $474 million in the Medical segment; GAAP diluted loss per share was $5.05, primarily due to this impairment, net of tax effectsNon-GAAP operating earnings decreased 21% to $545 million, primarily due to a decline in Medical segment profit; Non-GAAP diluted EPS decreased 5% to $1.45Finalized the previously announced national opioid settlement agreementCompany updates FY22 guidanceDUBLIN, Ohio, May 5, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2022 revenues of $44.8 billion, an increase of 14% from the third quarter of last

DUBLIN, Ohio, Feb. 8, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.4908 per share. The dividend will be payable on April 15, 2022 to shareholders of record at the close of business on April 1, 2022. About Cardinal Health Cardinal Health (NYSE:CAH) is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries

DUBLIN, Ohio, Feb. 3, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported second quarter fiscal year 2022 revenues of $45.5 billion, an increase of 9% from the second quarter of last year. Second quarter GAAP operating loss was $950 million due to a non-cash, pre-tax goodwill impairment of $1.3 billion related to the Medical segment. GAAP diluted earnings per share (EPS) were $0.17, primarily due to this impairment, net of tax effects. Second quarter non-GAAP operating earnings decreased 26% to $467 million and non-GAAP diluted earnings per share (EPS) decreased 27% to $1.27, primarily due to inflationary impacts and global supply chain constraints in the Medical segment.

DUBLIN, Ohio, Nov. 4, 2021 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.4908 per share. The dividend will be payable on January 15, 2022 to shareholders of record at the close of business on January 3, 2022. About Cardinal Health Cardinal Health (NYSE:CAH) is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 35

DUBLIN, Ohio, Aug. 5, 2021 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported that fourth-quarter fiscal 2021 revenue increased 16% to $42.6 billion. This increase includes the favorable prior year comparison from reduced pharmaceutical demand related to COVID-19. Fiscal year 2021 revenues were $162.5 billion, a 6% increase from fiscal year 2020. Both GAAP and Non-GAAP operating earnings during the fourth quarter and fiscal year 2021 were adversely impacted by a $197 million COVID-19-related inventory reserve related to certain Personal Protective Equipment (PPE) in the

DUBLIN, Ohio, May 6, 2021 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third-quarter fiscal year 2021 revenue of $39.3 billion, in-line with the third quarter of last year. Third-quarter GAAP operating earnings decreased 16% to $473 million, primarily due to the write-down of the net assets held for sale from the planned divestiture of the Cordis business. Third-quarter GAAP diluted earnings per share (EPS) decreased to $0.40, due to the previously-disclosed tax effect of the litigation charge in the first quarter. Non-GAAP operating earnings decreased 4% to $689

DUBLIN, Ohio, Feb. 5, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second-quarter fiscal year 2021 revenue of $41.5 billion, an increase of 5% from the second quarter of last year. Second-quarter GAAP operating earnings increased 38% to $461 million, primarily due to the beneficial comparison to the prior-year charge related to voluntary surgical gown recalls. GAAP diluted earnings per share (EPS) increased to $2.13, primarily due to the tax effect of a self-insurance loss. Non-GAAP operating earnings decreased 3% to $628 million in the quarter, and this decrease included a modest net negative impact from COVID-19. The Pharmaceutical segment was adversely affected by C